Compare CRL & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRL | APGE |
|---|---|---|
| Founded | 1947 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8B | 10.2B |
| IPO Year | 1999 | 2023 |
| Metric | CRL | APGE |
|---|---|---|
| Price | $288.50 | $135.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | ★ $198.27 | $109.67 |
| AVG Volume (30 Days) | 848.5K | ★ 1.3M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,857,601,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.48 | N/A |
| 52 Week Low | $144.26 | $35.39 |
| 52 Week High | $303.31 | $135.09 |
| Indicator | CRL | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 61.92 | 78.58 |
| Support Level | $215.89 | $134.03 |
| Resistance Level | $303.31 | N/A |
| Average True Range (ATR) | 9.54 | 0.10 |
| MACD | -2.67 | -0.39 |
| Stochastic Oscillator | 43.54 | 96.88 |
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.